Not exact matches
Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company
developing a new class
of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its
Phase 1b clinical trial
of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the
treatment of ocular melanoma, a rare and life - threatening disease.
Maastricht, The Netherlands, 1 November 2017 — Cristal Therapeutics, a clinical stage biopharmaceutical company
developing targeted nanomedicines for the
treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a
Phase 1b...
This study is the first
phase of a larger initiative to
develop and pilot test Critical Time Intervention, a transitional assistance model for individuals leaving residential substance abuse
treatment.
The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism
of action that might be suitable as combination
treatment with immunomodulatory
treatments... Further
phase 3 studies to measure the effect
of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to
develop trials
of progressive disease.»
«As
treatments for the earliest stages
of AMD are
developed in the coming years, correct identification
of AMD in primary eye care will be critical for routing patients to
treatment as soon as possible so that the disease can be treated in its earliest
phases and central vision loss avoided.»
Researchers at Massachusetts Eye and Ear / Harvard Medical School and the University
of Crete have conducted a
phase I / II clinical trial investigating the efficacy
of statins (cholesterol - lowering medications) for the
treatment of patients with the dry form
of age - related macular degeneration (AMD)-- the leading cause
of blindness in the
developed world.
An anti-PD-1 antibody
developed by Bristol - Myers Squibb generates excitement with results from a
phase I trial showing that, among 236 patients with various types
of cancer, the
treatment shrank tumors in 28 percent
of melanoma patients, 30 percent
of patients with kidney cancer, and 18 percent
of patients with advanced non-small cell lung cancer.
One
of the drugs I have
developed is currently in
Phase I human clinical trials for the
treatment of dry AMD.
Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and
developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE
Phase III clinical trial evaluating the safety and efficacy
of a single intravitreal injection
of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study
treatment.
The company is
developing a portfolio consisting
of four advanced product candidates, including pimavanserin, which is in
Phase III development for the
treatment of Parkinson's disease psychosis.
Several
developed countries will press for
phasing out a set
of hydrofluorocarbons (HFCs), the main refrigerants used in refrigeration, air - conditioning, cold - chains, fire extinguishers, defence equipment and some modes
of medical
treatment.
The
treatment plan is
developed after
phase 2, once the therapist has a good idea
of who the child is and how they view the world.